Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVAX NASDAQ:FTLF NASDAQ:KLRS NASDAQ:VRCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVAXEvaxion A/S$3.28+0.8%$3.75$2.45▼$12.15$27.31M0.2638,228 shs592 shsFTLFFitLife Brands$11.09+2.1%$10.43$8.67▼$20.98$104.10M0.0128,222 shs137 shsKLRSKalaris Therapeutics$4.67-1.0%$4.75$2.14▼$11.88$110.93M0.1976,981 shs237 shsVRCAVerrica Pharmaceuticals$6.35-4.0%$6.28$3.28▼$9.82$107.88M1.47103,140 shs2,493 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVAXEvaxion A/S-1.81%+1.56%-12.87%-20.92%+31.05%FTLFFitLife Brands-1.99%-1.36%+4.73%+10.03%-19.56%KLRSKalaris Therapeutics-2.48%+3.97%+12.95%-22.41%+82.56%VRCAVerrica Pharmaceuticals+9.06%+11.45%+10.52%+13.55%-23.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVAXEvaxion A/S$3.28+0.8%$3.75$2.45▼$12.15$27.31M0.2638,228 shs592 shsFTLFFitLife Brands$11.09+2.1%$10.43$8.67▼$20.98$104.10M0.0128,222 shs137 shsKLRSKalaris Therapeutics$4.67-1.0%$4.75$2.14▼$11.88$110.93M0.1976,981 shs237 shsVRCAVerrica Pharmaceuticals$6.35-4.0%$6.28$3.28▼$9.82$107.88M1.47103,140 shs2,493 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVAXEvaxion A/S-1.81%+1.56%-12.87%-20.92%+31.05%FTLFFitLife Brands-1.99%-1.36%+4.73%+10.03%-19.56%KLRSKalaris Therapeutics-2.48%+3.97%+12.95%-22.41%+82.56%VRCAVerrica Pharmaceuticals+9.06%+11.45%+10.52%+13.55%-23.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVAXEvaxion A/S 2.67Moderate Buy$11.00235.88% UpsideFTLFFitLife Brands 2.25Hold$21.5093.96% UpsideKLRSKalaris Therapeutics 2.78Moderate Buy$15.60234.41% UpsideVRCAVerrica Pharmaceuticals 2.25Hold$14.50128.20% UpsideCurrent Analyst Ratings BreakdownLatest EVAX, KLRS, VRCA, and FTLF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2026KLRSKalaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/23/2026KLRSKalaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/15/2026KLRSKalaris Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/11/2026EVAXEvaxion A/S Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/9/2026KLRSKalaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/4/2026FTLFFitLife Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/26/2026VRCAVerrica Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/13/2026KLRSKalaris Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/13/2026KLRSKalaris Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$26.00 ➝ $25.00(Data available from 7/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVAXEvaxion A/S$7.53M3.63N/AN/A$2.04 per share1.61FTLFFitLife Brands$90.85M1.15$1.17 per share9.50$4.65 per share2.38KLRSKalaris TherapeuticsN/AN/AN/AN/A$4.21 per shareN/AVRCAVerrica Pharmaceuticals$37.16M2.94N/AN/A$1.55 per share4.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVAXEvaxion A/S-$7.71M-$1.47N/A0.60N/AN/A-73.56%-37.45%8/20/2026 (Estimated)FTLFFitLife Brands$6.33M$0.6018.359.64N/A6.64%18.31%8.21%N/AKLRSKalaris Therapeutics-$43.44M-$2.15N/AN/AN/AN/A-72.78%-43.49%N/AVRCAVerrica Pharmaceuticals-$17.89M-$1.03N/AN/AN/A-47.97%-1,077.78%-40.76%8/11/2026 (Estimated)Latest EVAX, KLRS, VRCA, and FTLF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026FTLFFitLife Brands$0.14$0.17+$0.03$0.17N/A$25.33 million5/12/2026Q1 2026KLRSKalaris Therapeutics-$0.52-$0.46+$0.06-$0.46N/AN/A5/12/2026Q1 2026VRCAVerrica Pharmaceuticals-$0.59-$0.41+$0.18-$0.45$4.51 million$5.02 million5/7/2026Q1 2026EVAXEvaxion A/S-$0.01-$0.44-$0.43-$0.10$9.20 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEVAXEvaxion A/SN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/AKLRSKalaris TherapeuticsN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVAXEvaxion A/S0.415.855.85FTLFFitLife Brands0.781.520.49KLRSKalaris TherapeuticsN/A12.1912.19VRCAVerrica Pharmaceuticals0.032.101.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVAXEvaxion A/S11.04%FTLFFitLife Brands2.32%KLRSKalaris Therapeutics66.05%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipEVAXEvaxion A/S41.64%FTLFFitLife Brands61.70%KLRSKalaris Therapeutics68.10%VRCAVerrica Pharmaceuticals54.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVAXEvaxion A/S608.34 million4.87 millionNo DataFTLFFitLife Brands209.39 million3.60 millionNot OptionableKLRSKalaris Therapeutics11023.79 million7.59 millionN/AVRCAVerrica Pharmaceuticals4017.18 million7.90 millionNo DataEVAX, KLRS, VRCA, and FTLF HeadlinesRecent News About These CompaniesVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Recommendation of "Hold" by AnalystsJuly 1, 2026 | americanbankingnews.comVerrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment ...June 23, 2026 | markets.businessinsider.comVerrica Pharmaceuticals Announces First U.S. and Japanese Patients Dosed in Phase 3 COVE-3 Trial of YCANTH for Common WartsJune 22, 2026 | quiverquant.comQVerrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common WartsJune 22, 2026 | globenewswire.comVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comVerrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...May 13, 2026 | uk.finance.yahoo.comVerrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 13, 2026 | globenewswire.comVerrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comVerrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2026 | zacks.comVerrica Pharmaceuticals Reports First Quarter 2026 Financial ResultsMay 12, 2026 | globenewswire.comVerrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the ...May 6, 2026 | theglobeandmail.comVerrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual MeetingMay 5, 2026 | globenewswire.comVerrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate ...May 5, 2026 | bakersfield.comBVerrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026May 5, 2026 | globenewswire.comVerrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the ...April 10, 2026 | markets.businessinsider.comVerrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual MeetingApril 9, 2026 | globenewswire.comVerrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 6, 2026 | globenewswire.comVRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. - VRCAMarch 21, 2026 | tmcnet.comVRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law FirmMarch 20, 2026 | businesswire.comVRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCAMarch 20, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVAX, KLRS, VRCA, and FTLF Company DescriptionsEvaxion A/S NASDAQ:EVAX$3.28 +0.03 (+0.77%) As of 10:13 AM Eastern This is a fair market value price provided by Massive. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.FitLife Brands NASDAQ:FTLF$11.08 +0.23 (+2.07%) As of 10:15 AM Eastern This is a fair market value price provided by Massive. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.Kalaris Therapeutics NASDAQ:KLRS$4.66 -0.05 (-0.96%) As of 10:16 AM Eastern This is a fair market value price provided by Massive. Learn more.Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.Verrica Pharmaceuticals NASDAQ:VRCA$6.35 -0.27 (-4.02%) As of 10:14 AM Eastern This is a fair market value price provided by Massive. Learn more.Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rivian’s 75 Million-Share Offering Turns the R2 Growth Story Into a Dilution Test Sony Is Going All-Digital—But Investors Should Watch This Instead Scotiabank Sees a New Growth Story for Cloudflare Why Exxon Could Be the Market's Next Big Comeback Stock Why Penguin Solutions May Be the Smartest AI Infrastructure Stock The Market Just Got Shaken—These 3 ETFs May Come Out Stronger Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns A Market Panic Just Discounted the AI Highway's Tollbooth Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
